Success Story: EB-1A Approval for a Postdoctoral Researcher in the field of Molecular Pharmaceutical Science

Client’s Testimonial:

Thank you very much. Really appreciated your help and all the efforts you all had made. I have already recommended your team to my friends and some of them are already your clients. Of course, I will continue to refer friends to you. Thanks again for everything!
On November 12th, 2013 we received another EB1-A (Alien of Extraordinary Ability) Approval for a Postdoctoral Researcher in the field of Molecular Pharmaceutical Science (Approval Notice)


General Field: Molecular Pharmaceutical Science

Position at the Time of Case Filing: Postdoctoral Researcher

National Origin:  China

Service Center: Texas Service Center (TSC)

State of Residence at the Time of Filing:  North Carolina

Approval Notice Date: November 12, 2013

Processing Time:  5 months, 27 days (42 days after responding to RFE)


Case Summary:

The client in this case was a postdoctoral researcher from China in the field of molecular pharmaceutical science. Her work had primarily focused on the research of nanotechnology and drug delivery for the creation of novel therapeutics to treat various diseases.  At the time that we first starting working on her case, she did not have sufficient evidence for three criteria, as required in order to qualify under EB-1A.  We suggested that she review papers for journals while we prepared her case for filing, so that she would have sufficient evidence for the criterion regarding judging the work of others in her field.  Her work had resulted in at least 16 peer-reviewed scientific articles and, at the time that her case was filed, her publications had accumulated at least 413 citations, clearly demonstrating that she had influenced her field and garnered international acclaim.  In addition, she had conducted at least 6 paper reviews for journals related to the field of molecular pharmaceutical science by the time we filed her case. Of her accomplishments, one of her independent recommenders remarked, “Her phenomenal work in the field will yield innovative therapies for combatting genetic disorders, viral infections, and cancers and drawn together the study of biology and molecular pharmaceutical science.” It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that she sought to remain in the United States to continue work in the area of molecular pharmaceutical science, and that her continued research would substantially and prospectively benefit the United States. With the proof and documentation that we provided, her case was approved 42 days after responding to the RFE.